COPENHAGEN, Denmark, July 28, 2026
Antag Therapeutics announced that the first patient has been dosed in its Phase 2a clinical trial evaluating AT7687, the company’s first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist, in combination with semaglutide for the treatment of obesity and type 2 diabetes. The randomized, double-blind, placebo-controlled study will enroll 150 participants who are overweight or living with obesity and type 2 diabetes but are not currently receiving anti-obesity medications. Participants will receive either once-weekly subcutaneous AT7687 plus semaglutide dose escalation or placebo plus semaglutide over a 13-week treatment period, followed by a one-month safety follow-up. Topline results are expected during the first half of 2027.
Novel GIPR Antagonism Aims to Complement Existing Obesity Therapies
AT7687 is the first clinical-stage peptide-based GIP receptor antagonist designed to selectively block the GIP receptor, a genetically validated target associated with adiposity, insulin resistance, and cardiometabolic dysfunction. Unlike currently approved incretin therapies, the investigational therapy uses a distinct biological mechanism intended to complement existing GLP-1-based treatments rather than replace them. Antag Therapeutics believes GIP receptor antagonism could provide a more personalized treatment strategy by improving metabolic health while maintaining a favorable tolerability profile. The company expects this differentiated approach to expand therapeutic options for people living with obesity and type 2 diabetes, particularly as combination therapies become increasingly important in long-term metabolic disease management.
Study to Measure Weight Loss, Glycemic Control, and Cardiometabolic Health
The Phase 2a trial (NCT07724340) will primarily evaluate the change in body weight from randomization, with change in HbA1c serving as the key secondary endpoint to assess improvements in blood glucose control. Researchers will also analyze a broad range of secondary and exploratory endpoints, including biomarkers related to chronic inflammation, metabolic function, and long-term cardiovascular health. The multicenter study will be conducted across several clinical sites in the United States, providing important data on the potential of AT7687 as a combination therapy for patients requiring both effective weight management and improved glycemic control.
Advertisement
Positive Phase 1 Results Support Continued Clinical Development
The initiation of the Phase 2a study follows encouraging Phase 1 clinical results reported earlier in 2026, which demonstrated a favorable safety and tolerability profile across both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. Importantly, investigators reported no severe or serious adverse events and no gastrointestinal tolerability signals, a common challenge associated with many obesity therapies. Chief Executive Officer Philip Just Larsen stated that the study represents an important milestone in advancing more personalized obesity treatments, while Chief Medical Officer Richard Nkulikiyinka emphasized the growing role of combination therapies that balance efficacy, tolerability, and long-term metabolic health. Backed by €80 million in Series A financing, Antag Therapeutics continues to develop AT7687 as both a standalone therapy and a potential co-formulation with other obesity treatments, aiming to deliver flexible, patient-centered solutions for chronic metabolic diseases.
Source: Antag Therapeutics, press release
